BactiQuant (BACTIQ) H2 2025 earnings summary

Executive summary

• Revenue grew 16% year-over-year to DKK 8.3 million, driven by strong recurring sales and segment growth in Pharma and Aquaculture.

• EBITDA was negative DKK 10.9 million, in line with revised guidance, and net loss before tax was DKK 13.8 million.

• Two capital increases in 2025 raised a total net amount of DKK 30 million, significantly strengthening liquidity.

• The company ended 2025 with DKK 17.9 million in cash, ensuring liquidity through 2027.

Financial highlights

• Revenue: DKK 8.3 million (2024: DKK 7.2 million), up 16% year-over-year.

• EBITDA: DKK -10.9 million (2024: DKK -11.0 million).

• Net loss before tax: DKK -13.8 million (2024: DKK -13.7 million).

• Recurring revenue grew 14% to DKK 5.1 million; hardware sales declined 17% to DKK 1.8 million.

• Cash position at year-end: DKK 17.9 million (2024: DKK 0.85 million).

Outlook and guidance

• 2026 revenue guidance: DKK 10–13 million; EBITDA guidance: DKK -7 to -10 million.

• Guidance reflects current order backlog and expected new orders, with timing uncertainty for large contracts.